Medical News Article on StrokeDestination Therapy Trial Data...

Medical News Article on Stroke


Destination Therapy Trial Data Demonstrate Superiority for HeartMate II(R) Over HeartMate(R) XVE


2009 NOV 30 -- Thoratec Corporation (NASDAQ:THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said that data released from the Destination Therapy (DT) pivotal trial for the HeartMate II left ventricular assist system (LVAS) demonstrate that the device achieved statistically superior results over the HeartMate XVE, including survival at two years while remaining free from disabling stroke or the need for reoperation to replace or repair the pump. As treated survival was 58 percent for HeartMate II patients versus 24 percent for the HeartMate XVE patients.

The data were presented at a late...

In order to view the entire article, please read your options to the right